Skip to main content
Duke University Libraries
DukeSpace Scholarship by Duke Authors
  • Login
  • Ask
  • Menu
  • Login
  • Ask a Librarian
  • Search & Find
  • Using the Library
  • Research Support
  • Course Support
  • Libraries
  • About
View Item 
  •   DukeSpace
  • Theses and Dissertations
  • Undergraduate Honors Theses and Student papers
  • View Item
  •   DukeSpace
  • Theses and Dissertations
  • Undergraduate Honors Theses and Student papers
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

The Effect of Masitinib on Pediatric Glioblastoma

Thumbnail
Files
Thesis document
268.1 Kb
signed license
266.1 Kb
Date
2014
Author
Fleming, Tyler
Advisors
Cunningham, Cliff
Keir, Stephen
Repository Usage Stats
119
views
41
downloads
Abstract
Tumors of the Central Nervous System are the most prevalent pediatric solid tumor with gliomas being the most common and most aggressive form. The current standard of care involves a combination therapy with chemoradiation and gross tumor resection. The five-year survival rate of pediatric brain tumors is upwards of 70%, however, the combination of chemotherapy and radiation has proved to be harmful, especially to children, and in many cases significantly reduces their overall quality of life physically, socially and cognitively. As a result, finding ways to increase the efficacy of chemotherapy and/or radiation without increasing dosing is paramount in order to increase the life quality of survivors. Using a mouse model, this study investigated masitinib, a tyrosine kinase inhibitor, as a single agent and in combination with temozolomide, the current standard of care DNA alkylating agent, in the treatment of pediatric glioblastoma. This involved injection of patient derived pediatric glioblastoma xenografts into athymic nude mice and subsequent treatment of the mice with masitinib and/or temozolomide. Any possible chemosensitizing effects masitinib may have in a pediatric brain tumor xenograft model were also evaluated. The rationale for this combination is based on masitinib’s ability to effectively cross through the blood brain barrier and inhibit cell division in other types of cancer. While results indicated that masitinib does not work well as a single agent, it may in fact have cted as a chemosensitizer towards temozolomide, providing increased tumor growth delay relative to either drug used as a monotherapy. This finding warrants further investigation of masitinib in combination with temozolomide against pediatric glioblastoma.
Type
Honors thesis
Department
Biology
Subject
glioblastoma
pediatrics
Permalink
https://hdl.handle.net/10161/18379
Citation
Fleming, Tyler (2014). The Effect of Masitinib on Pediatric Glioblastoma. Honors thesis, Duke University. Retrieved from https://hdl.handle.net/10161/18379.
Collections
  • Undergraduate Honors Theses and Student papers
More Info
Show full item record
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.

Rights for Collection: Undergraduate Honors Theses and Student papers


Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info

Make Your Work Available Here

How to Deposit

Browse

All of DukeSpaceCommunities & CollectionsAuthorsTitlesTypesBy Issue DateDepartmentsAffiliations of Duke Author(s)SubjectsBy Submit DateThis CollectionAuthorsTitlesTypesBy Issue DateDepartmentsAffiliations of Duke Author(s)SubjectsBy Submit Date

My Account

LoginRegister

Statistics

View Usage Statistics
Duke University Libraries

Contact Us

411 Chapel Drive
Durham, NC 27708
(919) 660-5870
Perkins Library Service Desk

Digital Repositories at Duke

  • Report a problem with the repositories
  • About digital repositories at Duke
  • Accessibility Policy
  • Deaccession and DMCA Takedown Policy

TwitterFacebookYouTubeFlickrInstagramBlogs

Sign Up for Our Newsletter
  • Re-use & Attribution / Privacy
  • Harmful Language Statement
  • Support the Libraries
Duke University